Merck continues to prioritize the health and safety of employees and their families. Employees are encouraged to receive COVID-19 vaccination. If an employee qualifies for priority immunization, based on the local jurisdiction's criteria, Merck will make efforts to help the employee to receive the vaccine. In addition, all eligible in- and out-of-network services related to COVID-19 testing and treatment will be covered at 100%, with no deductible and no out-of-pocket costs.
In response to the COVID-19 crisis, Merck has temporarily lifted the 40-hour paid time off for volunteering limit, for employees who are trained in medical health care professions. In addition, public trust and confidence are at the core of successful immunization systems. Merck has joined the World Economic Forum’s coalition of like-minded employers committed to building and sustaining vaccine confidence and literacy in the workplace. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.
An affiliate of the U.S. Chamber of Commerce